Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus

Table 1 Pretreatment characteristics of the patients (n = 182)

Pretreatment characteristics	Values
Age1, yr	60.1 ± 14.1
Age ≥ 70 yr	27.40%
Sex, M : F	122:60
Body height1, cm	163.0 ± 8.9
Body weight1, kg	62.3 ± 12.1
Liver cirrhosis	26.60%
History of HCC	15.90%
FIB-4 index2	2.63 (0.45-19.03)
FIB-4 index > 3.25	40.70%
Wisteria floribunda agglutinin+-Mac-2 binding protein2	1.94 (0.20-18.51)
Hyaluronic acid2, ng/mL	97.4 (10.0-2750.0)
History of IFN-based therapy	23.60%
IL28B-SNP rs8099917 TT/non TT	136/38/8
ITPA-SNP rs1127354 CC	129/45/8
HCV genotype 2A/2B/ND	109/70/3
HCV RNA2, logIU/mL	6.1 (1.2-7.6)
HCV RNA > 6 logIU/mL	58.80%
White blood cell count2, /mm3	4575 (1700-12010)
Hemoglobin2, g/dL	13.7 (10.1-17.6)
Platelet count2, /mm3	165 (38-389) × 103
Aspartate aminotransferase2, IU/L	41 (14-336)
Alanine aminotransferase2, IU/L	40 (5-391)
Albumin2, g/dL	4.0 (2.6-5.0)
Total bilirubin2, mg/dL	0.8 (0.3-3.0)
Blood urea nitrogen2, mg/dL	13 (5-28)
Creatinine2, mg/dL	0.71 (0.32-1.23)
Estimated glomerular filtration rate2, mL/min/1.73 m2	78.9 (42.6-164.2)

¹Mean ± SD;

²Median (range). M: Male; F: Female; HCC: Hepatocellular carcinoma; FIB: Fibrosis; IL28B: Interleukin-28B; SNP: Single nucleotide polymorphisms; ITPA: Inosine triphosphate pyrophosphatase; HCV: Hepatitis C virus.

Table 2 Factors contributing to sustained virological response in the per protocol analysis

	Univariate			Multivariate
	Odds ratio	95%CI	P value	Odds ratio	95%CI	P value
Age, ≥ 70 yr	2.61	0.70, 9.82	0.1494
Sex, male	4.76	0.85, 88.89	0.0781
History of IFN-based therapy	5.12	1.39, 20.98	0.0147a	7.05	1.65, 36.08	0.0084a
Liver cirrhosis	6.72	1.78, 32.29	0.0048a	2.13	0.31, 14.34	0.4315
FIB-4 index, > 3.25	2.11	0.58, 8.54	0.2546
History of HCC	8.87	2.36, 37.04	0.0015a	7.67	1.30, 60.30	0.0233a
IL28B-SNP, non TT	1.21	0.17, 5.55	0.8214
ITPA-SNP, non CC	0.45	0.02, 2.63	0.4177
HCV genotype, 2A	2.78	0.67, 18.84	0.1687
Viral load, ≥ 6 logIU/mL	1.53	0.41, 7.31	0.5478
RBV dose reduction	2.29	0.47, 8.89	0.2757
Rapid virological response	0.86	0.22, 4.15	0.8401

^aP < 0.05, significant difference. IFN: Interferon; FIB: Fibrosis; HCC: Hepatocellular carcinoma; IL28B: Interleukin-28B; SNP: Single nucleotide polymorphisms; ITPA: Inosine triphosphate pyrophosphatase; HCV: Hepatitis C virus; RBV: Ribavirin.

Table 3 Assessment of patients with history of hepatitis C virus

	SVR (n = 23)	Non SVR (n = 6)	P value
Alpha fetoprotein	9.6 (1.7-348.9)	5.3 (2.6-65.7)	0.2815
Latest treatment for HCC			0.2558
Surgical resection or Radiofrequency ablation	73.9% (17)	66.6% (6)
Transcatheter arterial chemoembolization	26.1% (6)	16.7% (1)
Radiation for bone metastasis	0% (0)	16.7% (1)
Recurrent HCC within 1 yr from the end of SOF/RBV	65. 2% (15)	83.3% (5)	0.6328

SVR: Sustained virological response; HCC: Hepatocellular carcinoma; SOF/RBV: Sofosbuvir/ribavirin.